Upperton Pharma Solutions invest in the Futorque X-1 and O'Hara Labcoat
Upperton Pharma Solutions expand their Clinical manufacturing capabilities by investing in the KG-Pharma Futorque® X-1 and an O’Hara LabCoat™
Responding to customer demand, Upperton Pharma Solutions have strategically invested in new equipment for their GMP Clinical Manufacturing facility, to increase their capability and service offering in complete oral solid dosage production. S3 Process are delighted to be supporting them through this investment by introducing them to the new kg-pharma Futorque® X-1 and an O’Hara Labcoat™.
Upperton Pharma Solutions initially met with S3 Process at Making Pharma in 2019 where the Futorque® X-1 was on display in the UK for the first time. A few months later, Upperton attended the S3 Process OSD Technology seminar in Birmingham where they learnt more about the Red-Dot award winning tablet press from kg-pharma and O’Hara’s market-leading, tablet coating technology.
S3 Process have the reputation and experience in consulting on new equipment acquisitions and were able to support Upperton Pharma in their investment decision, as Duncan Betteley explains:
“During our initial discussions, it was clear that Upperton were looking for versatile GMP compliant equipment that allowed for maximum flexibility in tablet formulation development as well as providing a simple scale-up pathway. The Futorque®X-1 will be the perfect investment for Upperton Pharma Solutions, allowing tablet development with as little as 500g to GMP Clinical supply with outputs of up to 129,600 tablets/h. The O’Hara LabCoat™ is used in tablet R&D organisations and clinical manufacturing sites all over the UK and has a strong reputation for providing an excellent tablet coating process from a compact, portable and simple to use small scale coater”.
Upperton Pharma are a CDMO with over 20 years experience in the development of spray dried powder dosage forms. The KG Pharma Futorque® X-1 and the O’Hara LabCoat™ are the first in a string of equipment investments following MHRA approval for its GMP clinical manufacturing facility. Paul Kelsall, Director of Clinical Manufacture says:
‘This is an extremely exciting time for the business as we continue to expand on our GMP processing capabilities. We are always looking to increase our capabilities, in our people, plant and processing equipment and this is a huge step forward as we look to support our clients clinical manufacturing requirements. S3 Process have been crucial in identifying the right equipment, they know all the principal suppliers and are the best-placed people in the UK to make the relevant introductions. Their in-depth technical knowledge both of the equipment and our requirement means that from the outset they have a greater appreciation of which customisations are necessary for our process – making sure we don’t waste money on additions that we don’t need.”
Upperton Pharma Solutions develops and produces oral and inhalation drug products for clinical trials and is able to optimise formulation performance through a science-led approach to projects. Dr Ian Lafferty explains more about their choice of investment:
‘The investment in this high specification, versatile instrumented tablet machine provides Upperton Scientists with the equipment to manufacture clinical supplies and will also allow them to generate the data required to gain in-depth understanding and knowledge of process and formulation behaviour during compression that is key to supporting our clients during future scale-up, production and registration stages of their product development.’